US cancels trial after finding vaccine doesn't prevent HIV
from BioPharma Dive
The National Institutes of Health discontinued a South African trial of an HIV vaccine regimen after data monitors concluded the treatment hadn't prevented new infections. The HTVN 702 study stopped dosing following an interim analysis that was conducted when at least 60% of patients had been in the trial for 18 months. In the group given the vaccine, 129 patients were infected with HIV, while 123 were infected in the trial's placebo arm.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063